16:56 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting MENA could help treat metastases of serous ovarian cancer. In a panel of serous ovarian cancer cell lines, expression of the MENA isoform MENAΔv6 was...
04:20 , Dec 8, 2017 |  BC Week In Review  |  Company News

J&J opts in for Idorsia's hypertension candidate

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577) and its derivatives. Idorsia will be responsible for Phase III development and...
22:27 , Dec 4, 2017 |  BC Extra  |  Company News

J&J opts in for Idorsia's hypertension candidate

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577) and its derivatives. Idorsia will be responsible for Phase III development and...
21:49 , Jul 27, 2017 |  BC Innovations  |  Product R&D

Spheres of influence

AstraZeneca plc and Genentech Inc. have joined forces to test whether a liver spheroid system can improve upon the gold standard for preclinical prediction of hepatotoxicity. The goal is to raise the bar on preventing...
19:33 , Jun 16, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia rises in first trading day

Idorsia Ltd. (SIX:IDIA) gained CHF3.65 (37%) to CHF13.65 in its first day of trading on Friday. The closing price valued the company at CHF1.5 billion ($1.5 billion). Idorsia was spun out of Actelion Ltd. (SIX:ATLN),...
23:39 , Jun 9, 2017 |  BC Extra  |  Financial News

Actelion spinout Idorsia to list next week

On June 16, shares of Idorsia Ltd. (Allschwil, Switzerland) are to begin trading on the SIX Swiss Exchange. Idorsia will house the drug discovery and early clinical pipeline businesses of Actelion Ltd. (SIX:ATLN), which Johnson...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
19:40 , May 26, 2017 |  BC Week In Review  |  Clinical News

Actelion's endothelin receptor antagonist reduces blood pressure in Phase II

Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "significant dose-dependent" reductions in diastolic and systolic blood pressure in a double-blind Phase II trial to treat essential hypertension. In 410 evaluable patients in the per protocol (PP)...
20:39 , May 22, 2017 |  BC Extra  |  Clinical News

Actelion reports hypertension data amid Idorsia spinout

In a pipeline update outlining candidates it plans to spin out into newco Idorsia Ltd. , Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "statistically significant dose-dependent" reductions in both diastolic and systolic blood pressure in...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...